ClinicalTrials.gg
CompletedNCT02421939Updated Dec 4, 2025Results posted

A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation

A Phase 3 interventional study of gilteritinib and LoDAC (Low Dose Cytarabine) in Leukemia, Acute Myeloid (AML), sponsored by Astellas Pharma Global Development, Inc.. Completed at 126 sites in 14 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-04.

Sponsored by Astellas Pharma Global Development, Inc. (part of Astellas Pharma Inc) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
371
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 31 studies testing gilteritinib in Leukemia, Myeloid, Acute — 13 open to participants now, 15 under way, 6 of them phase 3. gilteritinib · Leukemia, Myeloid, Acute.

Enrollment
7th of 31
371 · median 97
Started
2015
with 2 others
Phase 3
8 of 31
3 open now
Registered
5th of 31
by date
Lead sponsor
10 of 31
Astellas Pharma Global Development, Inc.

Among the 31 studies testing gilteritinib in Leukemia, Myeloid, Acute, this one is the 7th largest by enrollment, is one of 3 that started in 2015, is one of 8 in phase 3, and was the 5th registered.

Leukemia, Myeloid, Acute

3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 817 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

13 of the 31 studies testing gilteritinib in Leukemia, Myeloid, Acute are open now, in 7 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 13 open studies →

About gilteritinib

gilteritinib: first FDA approval 2018 (XOSPATA), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 625 Leukemia, Myeloid, Acute studies recruiting now, 363 (58%) set no upper age limit and 222 (36%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies testing gilteritinib in Leukemia, Myeloid, Acute, or all of them as a file.
02

Study summary

The purpose of this study was to determine the clinical benefit of ASP2215 therapy in participants with FMS-like tyrosine kinase (FLT3) mutated acute myeloid leukemia (AML) who were refractory to or had relapsed after first-line AML therapy as shown with overall survival (OS) compared to salvage chemotherapy, and determined the efficacy of ASP2215 therapy as assessed by the rate of complete remission and complete remission with partial hematological recovery (CR/CRh) in these participants. This study also determined the overall efficacy in event-free survival (EFS) and complete remission (CR) rate of ASP2215 compared to salvage chemotherapy.

Read the detailed description

Participants considered an adult according to local regulations at the time of signing informed consent participated in this study. Participants were randomized in a 2:1 ratio to receive ASP2215 or salvage chemotherapy. Participants entered the screening period up to 14 days prior to the start of treatment. Prior to randomization, a salvage chemotherapy regimen was pre-selected for each participant; options included low-dose cytarabine (LoDAC), azacitidine, mitoxantrone, etoposide, and intermediate-dose cytarabine (MEC), or fludarabine, cytarabine, and granulocyte colony-stimulating factor (G-CSF) with idarubicin (FLAG-IDA). The randomization was stratified by response to first-line therapy and pre-selected salvage chemotherapy. Participants were administered treatment over continuous 28-day cycles. After treatment discontinuation, participants had a pre-hematopoietic stem cell transplant (HSCT)/end-of-treatment visit within 7 days after treatment discontinuation, followed by a 30-day follow-up for safety, in which a telephone contact with the participant was sufficient unless any assessment had to be repeated for resolution of treatment-related adverse events (AEs). After that, long term follow-up was done every 3 months up to 3 years from the participant's end-of-treatment visit.

03

Conditions studied

  • Leukemia, Acute Myeloid (AML)

Keywords

  • ASP2215
  • Relapsed Acute Myeloid Leukemia
  • FLT3 Mutation
  • gilteritinib
  • Refractory Acute Myeloid Leukemia
  • Acute Myeloid Leukemia (AML)
  • XOSPATA®
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant has a diagnosis of primary acute myeloid leukemia (AML) or AML secondary to myelodysplastic syndrome (MDS) according to WHO classification (2008) as determined by pathology review at the treating institute.
  • Participant is to or relapsed after AML therapy (with or without hematopoietic stem cell transplant ()).

    • Refractory to first-line AML therapy is defined as:

      1. Participant did not achieve complete remission/complete remission with incomplete hematologic recovery/complete remission with incomplete recovery (CR/CRi/CRp) under initial therapy. A Participant eligible for standard therapy must receive at least one cycle of an anthracycline containing induction block in standard dose for the selected induction regimen. A Participant not eligible for standard therapy must have received at least one complete block of induction therapy seen as the optimum choice of therapy to induce remission for this subject.

    • Untreated first hematologic relapse is defined as:

      1. Participant must have achieved a CR/CRi/CRp (criteria as defined by [Cheson et al, 2003], see Section 5.3) with first line treatment and has hematologic relapse.
  • Participant is positive for FLT3 mutation in bone marrow or whole blood as determined by the central lab. A Participant with rapidly proliferative disease and unable to wait for the central lab results can be enrolled based on a local test performed after completion of the last interventional treatment. Participants can be enrolled from a local test result if they have any of the following FLT3 mutations: FLT3 internal tandem duplication (ITD), FLT3 tyrosine kinase domain (TKD)/D835 or FLT3- TKD/I836.
  • Participant has an (ECOG) performance status ≤ 2.
  • Participant is eligible for pre-selected salvage chemotherapy.
  • Participant must meet the following criteria as indicated on the clinical laboratory tests:

    • Serum and alanine aminotransferase ≤ 2.5 x (ULN)
    • Serum total ≤ 1.5 x ULN
    • Serum creatinine ≤ 1.5 x ULN or an estimated of > 50 mL/min as calculated by the Modification of Diet in Renal Disease equation.
  • Participant is suitable for oral administration of study drug.
  • Female Participant must either:

    • Be of non-child bearing potential:

      1. (defined as at least 1 year without any menses) prior to Screening, or
      2. documented as surgically sterile (at least 1 month prior to Screening)
    • Or, if of ,

      1. Agree not to try to become pregnant during the study and for 180 days after the final study administration
      2. And have a negative urine pregnancy test at Screening
      3. And, if heterosexually active, agree to consistently use highly effective per locally accepted standards in addition to a barrier method starting at Screening and throughout the study period and for 180 days after the final study drug administration.
  • Female Participant must agree not to breastfeed at Screening and throughout the study period and for 60 days after the final study drug administration.
  • Female Participant must not donate ova starting at Screening and throughout the study period and for 180 days after the final study drug administration.
  • Male Participant and their female partners who are of childbearing potential must be using highly effective contraception per locally accepted standards in addition to a barrier method starting at Screening and continue throughout the study period and for 120 days after the final study drug administration.
  • Male Participant must not donate sperm starting at Screening and throughout the study period and 120 days after the final study drug administration.
  • Participant agrees not to participate in another interventional study while on treatment.

Exclusion criteria

Exclusion Criteria:

  • Participant was diagnosed as acute promyelocytic leukemia (APL).
  • Participant has BCR-ABL-positive leukemia (chronic myelogenous leukemia in blast crisis).
  • Participant has AML secondary to prior chemotherapy for other neoplasms (except for MDS).
  • Participant is in second or later hematologic relapse or has received salvage therapy for disease
  • Participant has clinically active central nervous system leukemia.
  • Participant has been diagnosed with another , unless disease-free for at least 5 years. Participants with treated nonmelanoma skin cancer, in situ carcinoma or cervical intraepithelial neoplasia, regardless of the disease-free duration, are eligible for this study if definitive treatment for the condition has been completed. Participants with organ-confined prostate cancer with no evidence of recurrent or progressive disease are eligible if hormonal therapy has been initiated or the malignancy has been surgically removed or treated with definitive radiotherapy.
  • Participant has received prior treatment with ASP2215 or other FLT3 inhibitors (with the exception of sorafenib and midostaurin used in therapy regimen as part of induction, consolidation, and/or maintenance).
  • Participant has abnormality of coagulation profile, such as disseminated intravascular coagulation (DIC).
  • Participant has had major surgery within 4 weeks prior to the first study dose.
  • Participant has radiation therapy within 4 weeks prior to the first study dose.
  • Participant has congestive heart failure (NYHA) class 3 or 4, or Participant with a history of congestive heart failure NYHA class 3 or 4 in the past, unless a screening echocardiogram performed within 3 months prior to study entry results in a that is ≥ 45%.
  • Participant requires treatment with concomitant drugs that are strong inducers of cytochrome P450 (CYP)3A.
  • Participants with mean of triplicate Fridericia- interval (QTcF) > 450 ms at Screening based on central reading.
  • Participants with Long QT Syndrome at Screening.
  • Participants with hypokalemia and hypomagnesemia at Screening (defined as values below lower limit of normal [LLN]).
  • Participant requires treatment with concomitant drugs that are strong inhibitors or inducers of P glycoprotein (P-gp) with the exception of drugs that are considered absolutely essential for the care of the subject.
  • Participant requires treatment with concomitant drugs that target serotonin 5-hydroxytryptamine receptor 1 (5HT1R) or 5-hydroxytryptamine receptor 2B (5HT2BR) or sigma nonspecific receptor with the exception of drugs that are considered absolutely essential for the care of the subject.
  • Participant has an active uncontrolled infection.
  • Participant is known to have infection.
  • Participant has active or C, or other active hepatic disorder.
  • Participant has any condition which makes the Participant unsuitable for study participation.
  • Participant has active clinically significant or is on treatment with systemic for GVHD.
  • Participant has an FLT3 mutation other than the following: FLT3-ITD, FLT3-TKD/D835 or FLT3-TKD/I836.
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
371 participants (actual)

Study arms

  • Experimental
    Gilteritinib

    Participants received 120 mg dose (3 tablets of 40 mg) orally once a day in continuous 28-day cycles, at least 2 hours after or 1 hour before food. Gilteritinib treatment continued until participants met one of the treatment discontinuation criteria.

    Drug: gilteritinib

  • Active comparator
    Salvage Chemotherapy

    Participants received chemotherapy in 28-day cycles. Participants on Low-Dose Cytarabine (LoDAC) received 20 mg of cytarabine twice daily by subcutaneous (SC) or intravenous (IV) injection for 10 days. Participants on azacitidine received 75 mg/m\^2 daily by SC or IV injection for 7 days. Participants on LoDAC or azacitidine treatment continued until they met discontinuation criteria. Participants on MEC chemotherapy received mitoxantrone 8 mg/m\^2 daily by IV for 5 days, etoposide 100 mg/m\^2 daily by IV for 5 days and cytarabine 1000 mg/m\^2 daily by IV for 5 days (days 1-5). Participants on FLAG-IDA chemotherapy received G-CSF 300 μg/m\^2 daily by SC/IV for 5 days (days 1-5), fludarabine 30 mg/m\^2 daily by IV for 5 days (days 2-6), cytarabine 2000 mg/m\^2 daily by IV for 5 days (days 2-6) and idarubicin 10 mg/m\^2 daily by IV for 3 days (days 2-4). Participants receiving MEC or FLAG-IDA received 1 cycle of therapy and were assessed for response on or after day 15.

    Drug: LoDAC (Low Dose Cytarabine) · Drug: Azacitidine · Drug: MEC (Mitoxantrone, Etoposide, Cytarabine) · Drug: FLAG-IDA (Granulocyte-Colony Stimulating Factor (G-CSF), Fludarabine, Cytarabine, Idarubicin)

Interventions

  • tablet, oral

    Also known as: ASP2215, XOSPATA®

  • DrugLoDAC (Low Dose Cytarabine)

    subcutaneous (SC) or intravenous (IV) injection

  • SC or IV injection

  • DrugMEC (Mitoxantrone, Etoposide, Cytarabine)

    IV injection

  • DrugFLAG-IDA (Granulocyte-Colony Stimulating Factor (G-CSF), Fludarabine, Cytarabine, Idarubicin)

    SC (G-CSF) and IV (Fludarabine, Cytarabine, Idarubicin) injection

06

What researchers measure

Primary outcomes

  1. Duration of Overall Survival (OS)

    Overall survival was defined as the time from the date of randomization until the date of death from any cause (death date - randomization date + 1). For a participant who was not known to have died by the end of study follow-up, OS was censored at the date of last contact (date of last contact - randomized date + 1). The date of last contact was the latest date that the participant was known to be alive. The last contact date was derived for participants alive at the analysis cutoff date. Survival rate and 95% CI were estimated using the Kaplan-Meier method and the Greenwood formula.

    Time frame: From randomization to until the date of death from any cause (median time of follow-up for OS was 17.8 months)

  2. Percentage of Participants With Complete Remission and Complete Remission With Partial Hematological Recovery (CR/CRh) in the Gilteritinib Arm

    The CR/CRh rate was defined as the number of participants who achieved either CR or CRh divided by the number of participants in the analysis population. CR: For participants to be classified as being in CR at, they must have had bone marrow regenerating normal hematopoietic cells and achieved a morphologic leukemia-free state and must had an ANC ≥ 1 x 10\^9/L and platelet count ≥ 100 x 10\^9/L and normal marrow differential with \< 5% blasts, and they were RBC and platelet transfusion independent (defined as 1 week without RBC transfusion and 1 week without platelet transfusion). There was no evidence of extramedullary leukemia. CRh: Participants were classified as CRh if they had marrow blasts \< 5%, partial hematologic recovery ANC ≥ 0.5 x 10\^9/L and platelets ≥ 50 x 10\^9/L, no evidence of extramedullary leukemia and could not be classified as CR.

    Time frame: From the date of randomization up to at least 112 days

Secondary outcomes

  1. Duration of Event-Free Survival (EFS)

    EFS: time from randomization date up to date of documented relapse (excluding relapse after PR)/ treatment failure (failure to achieve CR, CRp, CRi /PR) /death, whichever occurred first. Relapse: leukemic blasts in peripheral blood 5/ ≥ 25% blasts in bone marrow (BM) aspirate due to no other cause/reappearance/new appearance of extramedullary leukemia. CR: BM regenerating normal hematopoietic cells, morphologic leukemia-free state, ANC ≥1x10\^9/L, platelet count ≥100x10\^9/L, normal marrow differential with \<5% blasts, and RBC/platelet transfusion independent with no extramedullary leukemia. CRp: achieved CR except incomplete platelet recovery (\<100x 0\^9/L). CRi: criteria for CR fulfilled except incomplete hematological recovery with residual neutropenia \<1x10\^9/L with /without complete platelet recovery. PR: BM regenerating normal hematopoietic cells, peripheral recovery, no circulating blasts and decrease of 50% blasts in with total blasts between 5% -25% or, 5% if Auer rods present.

    Time frame: From the date of randomization until the date of documented relapse, treatment failure or death from any cause (median time of follow-up was 17.8 months)

  2. Percentage of Participants With Complete Remission (CR) Rate

    The CR rate was defined as the number of participants who achieved the best response of CR divided by the number of participants in the analysis population. CR: For participants to be classified as being in CR, they must have had bone marrow regenerating normal hematopoietic cells and achieved a morphologic leukemia-free state and must had an ANC ≥ 1 x 10\^9/L and platelet count ≥ 100 x 10\^9/L and normal marrow differential with \< 5% blasts, and they were RBC and platelet transfusion independent (defined as 1 week without RBC transfusion and 1 week without platelet transfusion). There was no evidence of extramedullary leukemia.

    Time frame: From the date of randomization up to at least 6 months

  3. Duration of Leukemia-Free Survival (LFS)

    LFS: time from the date of first CRc until the date of documented relapse or death for subjects who achieve CRc. For a subject who is not known to have relapsed or died, LFS is censored on the date of last relapse-free disease assessment date. CRc: achieved CR, CRp or CRi. Relapse: leukemic blasts in peripheral blood/ ≥ 25% blasts in bone marrow (BM) aspirate not due to any other cause/reappearance/new appearance of extramedullary leukemia. CR: BM regenerating normal hematopoietic cells, morphologic leukemia-free state, ANC ≥ 1 x 10\^9/L, platelet count ≥ 100 x 10\^9/L, normal marrow differential with \< 5% blasts, and RBC/platelet transfusion independent with no extramedullary leukemia. CRp: achieved CR except incomplete platelet recovery (\< 100 x 10\^9/L). CRi : criteria for CR fulfilled except incomplete hematological recovery with residual neutropenia \< 1 x 10\^9/L with /without complete platelet recovery..

    Time frame: From the date of first CRc until the date of documented relapse or death for participants who achieved CRc (median time of follow-up was 17.8 months)

  4. Duration of Remission

    Duration of remission included duration of CRc, CR/CRh, CRh, CR, CRi, CRp (defined as the time from the date of first CRc until the date of first documented relapse for participants who achieved CRc, CR/CRh, CRh, CR, CRi, CRp respectively) and duration of response (CRc + PR). CRc: achieved CR, CRp or CRi at the visit. CR: BM regenerating normal hematopoietic cells, morphologic leukemia-free state, ANC ≥1x10\^9/L, platelet count ≥100x10\^9/L, normal marrow differential with \<5% blasts, and RBC/platelet transfusion independent with no extramedullary leukemia. CRp: achieved CR except incomplete platelet recovery (\<100x 0\^9/L). CRi: criteria for CR fulfilled except incomplete hematological recovery with residual neutropenia \<1x10\^9/L with /without complete platelet recovery. PR: BM regenerating normal hematopoietic cells, peripheral recovery, no circulating blasts and decrease of 50% blasts in with total blasts between 5% -25% or, 5% if Auer rods present.

    Time frame: From the date of first response until the date of documented relapse for participants who achieved CRc or PR (median time of follow-up was 17.8 months)

  5. Percentage of Participants With Composite Complete Remission (CRc Rate)

    CRc rate: Number of participants with best response of CRc (CR,complete remission with incomplete platelet recovery \[CRp\] or complete remission with incomplete hematologic recovery \[CRi\]) divided by number of participants in the analysis population. CRc : Participants who achieved CR, CRp or CRi at a post-baseline visit. CR: Participants having bone marrow regenerating normal hematopoietic cells, a morphologic leukemia-free state, an ANC ≥ 1 x 10\^9/L and platelet count ≥ 100 x 10\^9/L, normal marrow differential with \< 5% blasts, and being RBC and platelet transfusion independent with no evidence of extramedullary leukemia at a post-baseline visit. CRp: Participants achieving CR except for incomplete platelet recovery (\< 100 x 10\^9/L) at a post-baseline visit. CRi : Participants, who fulfilled all criteria for CR except incomplete hematological recovery with residual neutropenia \< 1 x 10\^9/L with or without complete platelet recovery at a post-baseline visit.

    Time frame: From the date of randomization up to at least 6 months

  6. Percentage of Participants Who Underwent Hematopoietic Stem Cell Transplant

    Transplantation rate is defined as the percentage of participants undergoing Hematopoietic stem cell transplant (HSCT) during the study period.

    Time frame: From the date of randomization until end of study (median time of follow-up was 17.8 months)

  7. Change From Baseline in Brief Fatigue Inventory (BFI)

    The Brief Fatigue Inventory (BFI) was a screening tool designed to assess the severity and impact of fatigue on daily functioning of participants with cancer during the 24 hours. There are 9 items on the scale. The first three questions asked participants to rate their fatigues on a scale from 0 (no fatigue) - 10 (as bad as you can imagine), with higher scores indicating worse outcome. The remaining six questions asked participants to rate how much fatigue has interfered with their daily activities on a scale from 0 (Does not interfere) to 10 (Completely interferes). A global fatigue score can be obtained by averaging all the items on the BFI. The total score range is 0-10 with a higher BFI fatigue score indicates worse outcome. The global BFI score was calculated only if at least 5 of the 9 items are answered.

    Time frame: Baseline, Cycle 1 Day 8 and Cycle 2 Day 1

  8. Percentage of Participants With Complete Remission (CR) With Partial Hematological Recovery (CRh)

    CRh rate was defined as the number of participants who achieved CRh at any of the postbaseline visits and did not have a best response of CR divided by the number of participants in the analysis population. CR: For participants to be classified as being in CR at a post-baseline visit, they must have had bone marrow regenerating normal hematopoietic cells and achieved a morphologic leukemia-free state and must had an ANC ≥ 1 x 10\^9/L and platelet count ≥ 100 x 10\^9/L and normal marrow differential with \< 5% blasts, and they were RBC and platelet transfusion independent (defined as 1 week without RBC transfusion and 1 week without platelet transfusion). There was no evidence of extramedullary leukemia. CRh: At a post baseline visit, participantss were classified as CRh if they had marrow blasts \< 5%, partial hematologic recovery ANC ≥ 0.5 x 10\^9/L and platelets ≥ 50 x 10\^9/L, no evidence of extramedullary leukemia and could not be classified as CR.

    Time frame: From the date of randomization up to at least 6 months

  9. Percentage of Participants Who Achieved Transfusion Conversion and Maintenance

    Transfusion conversion \& maintenance rate was defined for gilteritinib arm. Participants were classified as transfusion independent if there were no RBC or platelet transfusions within 28 days prior to the first dose to 28 days after the first dose; otherwise they were classified as transfusion dependent at baseline. Participants were considered independent postbaseline if they had 1 consecutive 8 week period without any RBC or platelet transfusion from 29 days after the first dose until the last dose date. For participants who were on treatment ≤ 4 weeks or \> 4 weeks but \< 12 weeks and there was no RBC or platelet transfusion within postbaseline period, they were considered not evaluable; otherwise, they were considered postbaseline transfusion dependent. Transfusion conversion rate was defined for participants who had evaluable postbaseline transfusion status. Transfusion status (independent vs. dependent) at baseline and postbaseline was reported in a 2 by 2 contingency table.

    Time frame: From 29 days post first dose of study drug until last dose(median treatment duration was (126.00 [4.0, 885.0])

  10. Number of Participants With Treatment Emergent Adverse Events

    An AE was defined as any untoward medical occurrence in a participant, temporally associated with the use of study drug, whether or not related to it. It could be any unfavorable/unintended sign (including abnormal laboratory finding), symptom, or disease (new/exacerbated) temporally associated with use of the study drug. A treatment-emergent adverse event (TEAE) : AEs observed after starting administration of study drug (gilteritinib or salvage chemotherapy). Serious AEs (SAEs): AEs which caused death, were life-threatening, resulted in persistent/significant disability/incapacity or disruption of the ability to conduct normal life functions, congenital anomaly, birth defect, required inpatient hospitalization/led to prolongation of hospitalization. Based on national cancer institute common terminology criteria (NCI-CTCAE), AEs were graded as grade 1=mild, grade 2=moderate, grade 3 =severe or medically significant, grade 4 =life threatening, grade 5 =death related to AE

    Time frame: From first dose of study drug up to 30 days after the last dose of study drug (median treatment duration for gilteritinib was (126.00 [4.0, 885.0]) days versus salvage chemotherapy 28.0 [5.0, 217.0] days)

07

Results

Posted Oct 17, 2019

Participant flow

Participants were recruited from approximately 140 centers in North America, Europe, Asia and the rest of the world and randomized in a 2:1 ratio to receive gilteritinib or salvage chemotherapy. Participants had FMS-like tyrosine kinase 3 (FLT3) mutations and relapsed or refractory acute myeloid leukemia (AML) after first-line therapy.

Randomization Period: Up to 3 Years
Participant flow — Randomization Period: Up to 3 Years
MilestoneGilteritinibSalvage Chemotherapy
Started247124
Treated246109
Completed019
Not completed247105
Withdrew: Progressive disease7616
Withdrew: Lack of efficacy2131
Withdrew: Death3810
Withdrew: Disease relapse372
Withdrew: Adverse event325
Withdrew: Withdrawal by subject924
Withdrew: Physician decision1311
Withdrew: Protocol deviation11
Withdrew: Miscellaneous205
Long Term Follow up: up to 3 Years
Participant flow — Long Term Follow up: up to 3 Years
MilestoneGilteritinibSalvage Chemotherapy
Started13373
Completed00
Not completed13373
Withdrew: Withdrawal by subject45
Withdrew: Lost to follow-up12
Withdrew: Death11865
Withdrew: Miscellaneous101

Outcome measures

PrimaryDuration of Overall Survival (OS)

Overall survival was defined as the time from the date of randomization until the date of death from any cause (death date - randomization date + 1). For a participant who was not known to have died by the end of study follow-up, OS was censored at the date of last contact (date of last contact - randomized date + 1). The date of last contact was the latest date that the participant was known to be alive. The last contact date was derived for participants alive at the analysis cutoff date. Survival rate and 95% CI were estimated using the Kaplan-Meier method and the Greenwood formula.

Time frame:
From randomization to until the date of death from any cause (median time of follow-up for OS was 17.8 months)
Reported as:
Median · Months
Duration of Overall Survival (OS)
MonthsGilteritinibSalvage Chemotherapy
Duration of Overall Survival (OS)9.3 (7.7 to 10.7)5.6 (4.7 to 7.3)
Statistical analysis
  • Gilteritinib vs Salvage Chemotherapy · Log Rank · p = 0.0004 (1-sided P-value) · Hazard ratio (hr): 0.637 · 95% CI 0.490 to 0.830Based on Cox proportional hazards model. Assuming proportional hazards, an HR of \< 1 indicates a reduction in the hazard rate in favor of the gilteritinib arm
PrimaryPercentage of Participants With Complete Remission and Complete Remission With Partial Hematological Recovery (CR/CRh) in the Gilteritinib Arm

The CR/CRh rate was defined as the number of participants who achieved either CR or CRh divided by the number of participants in the analysis population. CR: For participants to be classified as being in CR at, they must have had bone marrow regenerating normal hematopoietic cells and achieved a morphologic leukemia-free state and must had an ANC ≥ 1 x 10\^9/L and platelet count ≥ 100 x 10\^9/L and normal marrow differential with \< 5% blasts, and they were RBC and platelet transfusion independent (defined as 1 week without RBC transfusion and 1 week without platelet transfusion). There was no evidence of extramedullary leukemia. CRh: Participants were classified as CRh if they had marrow blasts \< 5%, partial hematologic recovery ANC ≥ 0.5 x 10\^9/L and platelets ≥ 50 x 10\^9/L, no evidence of extramedullary leukemia and could not be classified as CR.

Time frame:
From the date of randomization up to at least 112 days
Reported as:
Number · Percentage of participants
Percentage of Participants With Complete Remission and Complete Remission With Partial Hematological Recovery (CR/CRh) in the Gilteritinib Arm
Percentage of participantsGilteritinib
CR/CRh rate28.2 (20.9 to 36.3)
CR rate19.0 (12.9 to 26.4)
CRh rate9.2 (5.0 to 15.1)
SecondaryDuration of Event-Free Survival (EFS)

EFS: time from randomization date up to date of documented relapse (excluding relapse after PR)/ treatment failure (failure to achieve CR, CRp, CRi /PR) /death, whichever occurred first. Relapse: leukemic blasts in peripheral blood 5/ ≥ 25% blasts in bone marrow (BM) aspirate due to no other cause/reappearance/new appearance of extramedullary leukemia. CR: BM regenerating normal hematopoietic cells, morphologic leukemia-free state, ANC ≥1x10\^9/L, platelet count ≥100x10\^9/L, normal marrow differential with \<5% blasts, and RBC/platelet transfusion independent with no extramedullary leukemia. CRp: achieved CR except incomplete platelet recovery (\<100x 0\^9/L). CRi: criteria for CR fulfilled except incomplete hematological recovery with residual neutropenia \<1x10\^9/L with /without complete platelet recovery. PR: BM regenerating normal hematopoietic cells, peripheral recovery, no circulating blasts and decrease of 50% blasts in with total blasts between 5% -25% or, 5% if Auer rods present.

Time frame:
From the date of randomization until the date of documented relapse, treatment failure or death from any cause (median time of follow-up was 17.8 months)
Reported as:
Median · Months
Duration of Event-Free Survival (EFS)
MonthsGilteritinibSalvage Chemotherapy
Duration of Event-Free Survival (EFS)2.8 (1.4 to 3.7)0.7 (0.2 to NA)
Statistical analysis
  • Gilteritinib vs Salvage Chemotherapy · Log Rank · p = 0.0415 (1-sided P-value) · Hazard ratio (hr): 0.793 · 95% CI 0.577 to 1.089Based on the Cox proportional hazards model. Assuming proportional hazards, an HR of \< 1 indicates a reduction in the hazard rate in favor of the gilteritinib arm.
SecondaryPercentage of Participants With Complete Remission (CR) Rate

The CR rate was defined as the number of participants who achieved the best response of CR divided by the number of participants in the analysis population. CR: For participants to be classified as being in CR, they must have had bone marrow regenerating normal hematopoietic cells and achieved a morphologic leukemia-free state and must had an ANC ≥ 1 x 10\^9/L and platelet count ≥ 100 x 10\^9/L and normal marrow differential with \< 5% blasts, and they were RBC and platelet transfusion independent (defined as 1 week without RBC transfusion and 1 week without platelet transfusion). There was no evidence of extramedullary leukemia.

Time frame:
From the date of randomization up to at least 6 months
Reported as:
Number · Percentage of participants
Percentage of Participants With Complete Remission (CR) Rate
Percentage of participantsGilteritinibSalvage Chemotherapy
Percentage of Participants With Complete Remission (CR) Rate21.1 (16.1 to 26.7)10.5 (5.7 to 17.3)
Statistical analysis
  • Gilteritinib vs Salvage Chemotherapy · Cochran-Mantel-Haenszel · p = 0.0106 (Stratified P-value) · Adjusted treatment difference: 10.6 · 95% CI 2.8 to 18.4
SecondaryDuration of Leukemia-Free Survival (LFS)

LFS: time from the date of first CRc until the date of documented relapse or death for subjects who achieve CRc. For a subject who is not known to have relapsed or died, LFS is censored on the date of last relapse-free disease assessment date. CRc: achieved CR, CRp or CRi. Relapse: leukemic blasts in peripheral blood/ ≥ 25% blasts in bone marrow (BM) aspirate not due to any other cause/reappearance/new appearance of extramedullary leukemia. CR: BM regenerating normal hematopoietic cells, morphologic leukemia-free state, ANC ≥ 1 x 10\^9/L, platelet count ≥ 100 x 10\^9/L, normal marrow differential with \< 5% blasts, and RBC/platelet transfusion independent with no extramedullary leukemia. CRp: achieved CR except incomplete platelet recovery (\< 100 x 10\^9/L). CRi : criteria for CR fulfilled except incomplete hematological recovery with residual neutropenia \< 1 x 10\^9/L with /without complete platelet recovery..

Time frame:
From the date of first CRc until the date of documented relapse or death for participants who achieved CRc (median time of follow-up was 17.8 months)
Reported as:
Median · Months
Duration of Leukemia-Free Survival (LFS)
MonthsGilteritinibSalvage Chemotherapy
Duration of Leukemia-Free Survival (LFS)4.4 (3.6 to 5.2)6.7 (2.1 to 8.5)
Statistical analysis
  • Gilteritinib vs Salvage Chemotherapy · Log Rank · p = 0.6654 (Unstratified p-value) · Hazard ratio (hr): 0.889 · 95% CI 0.506 to 1.563Based on the Cox proportional hazards model. Assuming proportional hazards, an HR of \< 1 indicates a reduction in the hazard rate in favor of the gilteritinib arm.
SecondaryDuration of Remission

Duration of remission included duration of CRc, CR/CRh, CRh, CR, CRi, CRp (defined as the time from the date of first CRc until the date of first documented relapse for participants who achieved CRc, CR/CRh, CRh, CR, CRi, CRp respectively) and duration of response (CRc + PR). CRc: achieved CR, CRp or CRi at the visit. CR: BM regenerating normal hematopoietic cells, morphologic leukemia-free state, ANC ≥1x10\^9/L, platelet count ≥100x10\^9/L, normal marrow differential with \<5% blasts, and RBC/platelet transfusion independent with no extramedullary leukemia. CRp: achieved CR except incomplete platelet recovery (\<100x 0\^9/L). CRi: criteria for CR fulfilled except incomplete hematological recovery with residual neutropenia \<1x10\^9/L with /without complete platelet recovery. PR: BM regenerating normal hematopoietic cells, peripheral recovery, no circulating blasts and decrease of 50% blasts in with total blasts between 5% -25% or, 5% if Auer rods present.

Time frame:
From the date of first response until the date of documented relapse for participants who achieved CRc or PR (median time of follow-up was 17.8 months)
Reported as:
Median · Months
Duration of Remission
MonthsGilteritinibSalvage Chemotherapy
Duration of Remission14.8 (11.0 to NA)1.8 (NA to NA)
Statistical analysis
  • Gilteritinib vs Salvage Chemotherapy · Log Rank · p = 0.1189 (Unstratified) · Hazard ratio (hr): 0.206 · 95% CI 0.022 to 1.886Based on Cox proportional hazards model. Assuming proportional hazards, a hazard ratio \< 1 indicates a reduction in hazard rate in favor of gilteritinib arm.
SecondaryPercentage of Participants With Composite Complete Remission (CRc Rate)

CRc rate: Number of participants with best response of CRc (CR,complete remission with incomplete platelet recovery \[CRp\] or complete remission with incomplete hematologic recovery \[CRi\]) divided by number of participants in the analysis population. CRc : Participants who achieved CR, CRp or CRi at a post-baseline visit. CR: Participants having bone marrow regenerating normal hematopoietic cells, a morphologic leukemia-free state, an ANC ≥ 1 x 10\^9/L and platelet count ≥ 100 x 10\^9/L, normal marrow differential with \< 5% blasts, and being RBC and platelet transfusion independent with no evidence of extramedullary leukemia at a post-baseline visit. CRp: Participants achieving CR except for incomplete platelet recovery (\< 100 x 10\^9/L) at a post-baseline visit. CRi : Participants, who fulfilled all criteria for CR except incomplete hematological recovery with residual neutropenia \< 1 x 10\^9/L with or without complete platelet recovery at a post-baseline visit.

Time frame:
From the date of randomization up to at least 6 months
Reported as:
Number · Percentage of participants
Percentage of Participants With Composite Complete Remission (CRc Rate)
Percentage of participantsGilteritinibSalvage Chemotherapy
Percentage of Participants With Composite Complete Remission (CRc Rate)54.3 (47.8 to 60.6)21.8 (14.9 to 30.1)
Statistical analysis
  • Gilteritinib vs Salvage Chemotherapy · 2-sided Fisher's exact test · p = <0.0001 (Unstratified 2-sided P-value) · Treatment difference: 32.5 · 95% CI 22.3 to 42.6
SecondaryPercentage of Participants Who Underwent Hematopoietic Stem Cell Transplant

Transplantation rate is defined as the percentage of participants undergoing Hematopoietic stem cell transplant (HSCT) during the study period.

Time frame:
From the date of randomization until end of study (median time of follow-up was 17.8 months)
Reported as:
Number · Percentage of participants
Percentage of Participants Who Underwent Hematopoietic Stem Cell Transplant
Percentage of participantsGilteritinibSalvage Chemotherapy
Percentage of Participants Who Underwent Hematopoietic Stem Cell Transplant25.5 (20.2 to 31.4)15.3 (9.5 to 22.9)
Statistical analysis
  • Gilteritinib vs Salvage Chemotherapy · 2-sided Fisher's exact test · p = 0.0333 (Unstratified 2-sided P-value.) · Treatment difference: 10.2 · 95% CI 1.2 to 19.1Treatment difference = gilteritinib - chemotherapy.
SecondaryChange From Baseline in Brief Fatigue Inventory (BFI)

The Brief Fatigue Inventory (BFI) was a screening tool designed to assess the severity and impact of fatigue on daily functioning of participants with cancer during the 24 hours. There are 9 items on the scale. The first three questions asked participants to rate their fatigues on a scale from 0 (no fatigue) - 10 (as bad as you can imagine), with higher scores indicating worse outcome. The remaining six questions asked participants to rate how much fatigue has interfered with their daily activities on a scale from 0 (Does not interfere) to 10 (Completely interferes). A global fatigue score can be obtained by averaging all the items on the BFI. The total score range is 0-10 with a higher BFI fatigue score indicates worse outcome. The global BFI score was calculated only if at least 5 of the 9 items are answered.

Time frame:
Baseline, Cycle 1 Day 8 and Cycle 2 Day 1
Reported as:
Mean · Units on a scale
Change From Baseline in Brief Fatigue Inventory (BFI)
Units on a scaleGilteritinibSalvage Chemotherapy
Cycle 1 day 8 (C1D8)-0.4 ± 2.11.0 ± 2.3
Cycle 2 day 1 (C2D1)0.0 ± 2.60.4 ± 2.8
Statistical analysis
  • Gilteritinib vs Salvage Chemotherapy · ANCOVA · p = 0.0000 · Least squares mean difference: -1.2567
  • Gilteritinib vs Salvage Chemotherapy · ANCOVA · p = 0.8037 · Least squares mean difference: 0.1574
SecondaryPercentage of Participants With Complete Remission (CR) With Partial Hematological Recovery (CRh)

CRh rate was defined as the number of participants who achieved CRh at any of the postbaseline visits and did not have a best response of CR divided by the number of participants in the analysis population. CR: For participants to be classified as being in CR at a post-baseline visit, they must have had bone marrow regenerating normal hematopoietic cells and achieved a morphologic leukemia-free state and must had an ANC ≥ 1 x 10\^9/L and platelet count ≥ 100 x 10\^9/L and normal marrow differential with \< 5% blasts, and they were RBC and platelet transfusion independent (defined as 1 week without RBC transfusion and 1 week without platelet transfusion). There was no evidence of extramedullary leukemia. CRh: At a post baseline visit, participantss were classified as CRh if they had marrow blasts \< 5%, partial hematologic recovery ANC ≥ 0.5 x 10\^9/L and platelets ≥ 50 x 10\^9/L, no evidence of extramedullary leukemia and could not be classified as CR.

Time frame:
From the date of randomization up to at least 6 months
Reported as:
Number · Percentage of participants
Percentage of Participants With Complete Remission (CR) With Partial Hematological Recovery (CRh)
Percentage of participantsGilteritinibSalvage Chemotherapy
Percentage of Participants With Complete Remission (CR) With Partial Hematological Recovery (CRh)34.0 (28.1 to 40.3)15.3 (9.5 to 22.9)
Statistical analysis
  • Gilteritinib vs Salvage Chemotherapy · Cochran-Mantel-Haenszel · p = <0.0171 (Stratified 1-sided P-value.) · Adjusted treatment difference,: 18.6 · 95% CI 9.8 to 27.4
SecondaryPercentage of Participants Who Achieved Transfusion Conversion and Maintenance

Transfusion conversion \& maintenance rate was defined for gilteritinib arm. Participants were classified as transfusion independent if there were no RBC or platelet transfusions within 28 days prior to the first dose to 28 days after the first dose; otherwise they were classified as transfusion dependent at baseline. Participants were considered independent postbaseline if they had 1 consecutive 8 week period without any RBC or platelet transfusion from 29 days after the first dose until the last dose date. For participants who were on treatment ≤ 4 weeks or \> 4 weeks but \< 12 weeks and there was no RBC or platelet transfusion within postbaseline period, they were considered not evaluable; otherwise, they were considered postbaseline transfusion dependent. Transfusion conversion rate was defined for participants who had evaluable postbaseline transfusion status. Transfusion status (independent vs. dependent) at baseline and postbaseline was reported in a 2 by 2 contingency table.

Time frame:
From 29 days post first dose of study drug until last dose(median treatment duration was (126.00 [4.0, 885.0])
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieved Transfusion Conversion and Maintenance
Percentage of participantsGilteritinib
Baseline Independent/ Post baseline Independent59.2
Baseline Independent/Post baseline Dependent24.5
Baseline Independent/Post baseline Not Evaluable16.3
Baseline Dependent/Post baseline Independent34.5
Baseline Dependent/Post baseline Dependent55.8
Baseline Dependent/Post baseline Not Evaluable9.6
SecondaryNumber of Participants With Treatment Emergent Adverse Events

An AE was defined as any untoward medical occurrence in a participant, temporally associated with the use of study drug, whether or not related to it. It could be any unfavorable/unintended sign (including abnormal laboratory finding), symptom, or disease (new/exacerbated) temporally associated with use of the study drug. A treatment-emergent adverse event (TEAE) : AEs observed after starting administration of study drug (gilteritinib or salvage chemotherapy). Serious AEs (SAEs): AEs which caused death, were life-threatening, resulted in persistent/significant disability/incapacity or disruption of the ability to conduct normal life functions, congenital anomaly, birth defect, required inpatient hospitalization/led to prolongation of hospitalization. Based on national cancer institute common terminology criteria (NCI-CTCAE), AEs were graded as grade 1=mild, grade 2=moderate, grade 3 =severe or medically significant, grade 4 =life threatening, grade 5 =death related to AE

Time frame:
From first dose of study drug up to 30 days after the last dose of study drug (median treatment duration for gilteritinib was (126.00 [4.0, 885.0]) days versus salvage chemotherapy 28.0 [5.0, 217.0] days)
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events
ParticipantsGilteritinibSalvage Chemotherapy
Drug-related TEAE20871
Serious TEAE21134
Drug-related serious TEAE9216
TEAE leading to death7616
Drug-related TEAE leading to death115
TEAE leading to withdrawal of treatment6513
Drug-related TEAE lead withdrawal of treatment305
NCI-CTCAE Grade 3 or higher TEAE23894
Drug-related Grade 3 or higher TEAE15757
Death20387

Adverse events

Collected over Adverse events: From first dose of study drug up to 30 days after the last dose of study drug (median treatment duration for gilteritinib was (126.00 [4.0, 885.0]) days versus salvage chemotherapy 28.0 [5.0, 217.0] days) All cause mortality: From randomization up to end of study (approximately 112 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Gilteritinib204/247 (82.6%)211/246 (85.8%)242/246 (98.4%)
Salvage Chemotherapy96/124 (77.4%)34/109 (31.2%)103/109 (94.5%)
Most frequent serious events
Showing 10 of 293
Most frequent serious events
EventGilteritinibSalvage Chemotherapy
Febrile neutropeniaBlood and lymphatic system disorders76/2469/109
PneumoniaInfections and infestations43/2468/109
Acute myeloid leukaemiaNeoplasms benign, malignant and unspecified (incl cysts and polyps)35/2464/109
PyrexiaGeneral disorders34/2461/109
SepsisInfections and infestations19/2467/109
Acute kidney injuryRenal and urinary disorders18/2464/109
Alanine aminotransferase increasedInvestigations13/2460/109
DiarrhoeaGastrointestinal disorders11/2460/109
BacteraemiaInfections and infestations10/2461/109
Septic shockInfections and infestations10/2461/109
Most frequent other events
Showing 10 of 93
Most frequent other events
EventGilteritinibSalvage Chemotherapy
AnaemiaBlood and lymphatic system disorders112/24638/109
Alanine aminotransferase increasedInvestigations100/24610/109
Aspartate aminotransferase increasedInvestigations97/24613/109
PyrexiaGeneral disorders93/24631/109
NauseaGastrointestinal disorders83/24636/109
DiarrhoeaGastrointestinal disorders82/24632/109
ConstipationGastrointestinal disorders77/24616/109
HypokalaemiaMetabolism and nutrition disorders72/24633/109
Febrile neutropeniaBlood and lymphatic system disorders57/24632/109
CoughRespiratory, thoracic and mediastinal disorders72/24611/109

Baseline characteristics

The analysis population was the Intention to Treatment (ITT), which consisted of all randomized participants.

Age, Continuous
Age, Continuous(Years)GilteritinibSalvage ChemotherapyTotal
Mean59 ± 14.657.6 ± 14.858.5 ± 14.7
Sex: Female, Male
Sex: Female, Male(Participants)GilteritinibSalvage ChemotherapyTotal
Female13170201
Male11654170
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)GilteritinibSalvage ChemotherapyTotal
WHITE14575220
ASIAN6933102
BLACK OR AFRICAN AMERICAN14721
NATIVE HAWAIIAN OR OTHER PACIFIC ISLANDER101
AMERICAN INDIAN OR ALASKA NATIVE000
UNKNOWN448
OTHER516
MISSING9413
Ethnicity
Ethnicity(Participants)GilteritinibSalvage ChemotherapyTotal
NOT HISPANIC OR LATINO221116337
HISPANIC OR LATINO12214
UNKNOWN325
MISSING11415
Cytogenic Risk Status
Cytogenic Risk Status(Participants)GilteritinibSalvage ChemotherapyTotal
INTERMEDIATE18289271
UNFAVORABLE261137
FAVORABLE415
OTHER352358
Baseline Eastern Cooperative Oncology Group (ECOG)
Baseline Eastern Cooperative Oncology Group (ECOG)(Participants)GilteritinibSalvage ChemotherapyTotal
0-1206105311
>=2411960
FLT3 Mutation Status by Central Testing by FLT3 CDx
FLT3 Mutation Status by Central Testing by FLT3 CDx(Participants)GilteritinibSalvage ChemotherapyTotal
FLT3-ITD Alone215113328
FLT3-TKD Alone211031
FLT3-ITD and FLT3-TKD707
Others (Unknown/Missing/Negative)415
Prior Use of FLT3 Inhibitor
Prior Use of FLT3 Inhibitor(Participants)GilteritinibSalvage ChemotherapyTotal
No215110325
Yes321446

7 further baseline measures are reported on the registry.

08

Study locations

126 sites
  • Site US10011
    Birmingham, Alabama 35294-0006, United States
  • Site US10012
    Los Angeles, California 90095-1752, United States
  • Site US10076
    Orange, California 92868, United States
  • Site US10073
    San Francisco, California 94143, United States
  • Site US10067
    New Haven, Connecticut 06504, United States
  • Site US10045
    Gainesville, Florida 32610, United States
  • Site US10081
    Atlanta, Georgia 30342, United States
  • Site US10006
    Chicago, Illinois 60637, United States
  • Site US10075
    Westwood, Kansas 66205, United States
  • Site US10074
    Louisville, Kentucky 40202, United States
  • Site US10048
    New Orleans, Louisiana 70112, United States
  • Site US10005
    Baltimore, Maryland 21201, United States
  • Site US10034
    Boston, Massachusetts 02114, United States
  • Site US10022
    Boston, Massachusetts 02215, United States
  • Site US10085
    Boston, Massachusetts 02215, United States
  • Site US10087
    Detroit, Michigan 48201, United States
  • Site US10057
    Minneapolis, Minnesota 55455, United States
  • Site US10023
    Lebanon, New Hampshire 03756-1000, United States
  • Site US10027
    Hackensack, New Jersey 07601, United States
  • Site US10077
    New Brunswick, New Jersey 08903, United States
  • Site US10001
    Buffalo, New York 14263, United States
  • Site US10037
    New York, New York 10029, United States
  • Site US10008
    New York, New York 10032, United States
  • Site US10013
    New York, New York 10065, United States
  • Site US10072
    New York, New York 10065, United States
  • Site US10046
    Syracuse, New York 13210, United States
  • Site US10024
    Durham, North Carolina 27710, United States
  • Site US10078
    Winston-Salem, North Carolina 27157, United States
  • Site US10044
    Cleveland, Ohio 44106, United States
  • Site US10084
    Columbus, Ohio 43210, United States
  • Site US10058
    Oklahoma City, Oklahoma 73104, United States
  • Site US10041
    Hershey, Pennsylvania 17033, United States
  • Site US10010
    Philadelphia, Pennsylvania 19104, United States
  • Site US10080
    Philadelphia, Pennsylvania 19107, United States
  • Site US10014
    Charleston, South Carolina 29425, United States
  • Site US10063
    Nashville, Tennessee 37232-0656, United States
  • Site US10035
    Milwaukee, Wisconsin 53226, United States
  • Site BE32002
    Yvoir, 5530, Belgium
  • Site CA15004
    Edmonton, Alberta T6G 2G3, Canada
  • Site CA15001
    Hamilton, Ontario L8V 1C3, Canada
  • Site CA15015
    Toronto, Ontario M5G 2M9, Canada
  • Site CA15003
    Montreal, Quebec H1T 2M4, Canada
  • Site FR33013
    Brest, 29609, France
  • Site FR33002
    Le Chesnay, 78157, France
  • Site FR33010
    Lille, 59037, France
  • Site FR33009
    Pessac, 33604, France
  • Site FR33014
    Rennes, 35033, France
  • Site FR33008
    Toulouse, 31059, France
  • Site DE49009
    Dresden, 01307, Germany
  • Site DE49011
    Leipzig, 04103, Germany
  • Site DE49003
    Marburg, 35043, Germany
  • Site DE49002
    München, 81737, Germany
  • Site DE49010
    Tübingen, 72076, Germany
  • Site IL97201
    Ashkelon, 78278, Israel
  • Site IL97209
    Haifa, 31096, Israel
  • Site IL97203
    Jerusalem, 91031, Israel
  • Site IL97210
    Jerusalem, 91120, Israel
  • Site IL97206
    Petah Tikva, 49100, Israel
  • Site IL97208
    Rehovot, 76100, Israel
  • Site IT39005
    Bologna, 40138, Italy
  • Site IT39010
    Brescia, 25126, Italy
  • Site IT39001
    Milan, 20132, Italy
  • Site IT39004
    Palermo, 90146, Italy
  • Site IT39011
    Pavia, 27100, Italy
  • Site IT39007
    Roma, 00189, Italy
  • Site IT39002
    Varese, 21100, Italy
  • Site JP81002
    Nagoya, Aichi-ken, Japan
  • Site JP81010
    Narita, Chiba, Japan
  • Site JP81026
    Yoshida-gun, Fukui, Japan
  • Site JP81016
    Sapporo, Hokkaido, Japan
  • Site JP81018
    Kobe, Hyōgo, Japan
  • Site JP81017
    Tsukuba, Ibaraki, Japan
  • Site JP81009
    Isehara, Kanagawa, Japan
  • Site JP81006
    Yokohama, Kanagawa, Japan
  • Site JP81012
    Sendai, Miyagi, Japan
  • Site JP81007
    Kurashiki, Okayama-ken, Japan
  • Site JP81014
    Sayama, Osaka, Japan
  • Site JP81020
    Kawagoe, Saitama, Japan
  • Site JP81027
    Shimotsuke, Tochigi, Japan
  • Site JP81005
    Chuo-ku, Tokyo, Japan
  • Site JP81004
    Shinagawa-ku, Tokyo, Japan
  • Site JP81022
    Shinjuku-ku, Tokyo, Japan
  • Site JP81023
    Akita, Japan
  • Site JP81021
    Aomori, Japan
  • Site JP81013
    Kumamoto, Japan
  • Site JP81025
    Kyoto, Japan
  • Site JP81008
    Nagasaki, Japan
  • Site JP81024
    Okayama, Japan
  • Site JP81011
    Osaka, Japan
  • Site PL48002
    Gdansk, 80-952, Poland
  • Site PL48005
    Opole, 45-372, Poland
  • Site PL48004
    Wroclaw, 50-367, Poland
  • Site KR82005
    Suwon, Gyeonggi-do 443380, South Korea
  • Site KR82010
    Busan, 602739, South Korea
  • Site KR82009
    Goyang, 602-715, South Korea
  • Site KR82003
    Jeollanam-do, 519-809, South Korea
  • Site KR82007
    Seoul, 110-744, South Korea
  • Site KR82004
    Seoul, 120-752, South Korea
  • Site KR82001
    Seoul, 135710, South Korea
  • Site KR82002
    Seoul, 137701, South Korea

Showing the first 100 of 126 sites across 14 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Ritchie EK, Cella D, Fabbiano F, Pigneux A, Kanda Y, Ivanescu C, Pandya BJ, Shah MV. Patient-reported outcomes from the phase 3 ADMIRAL trial in patients with FLT3-mutated relapsed/refractory AML. Leuk Lymphoma. 2023 May;64(5):938-950. doi: 10.1080/10428194.2023.2186731. Epub 2023 Apr 5. PubMed 37019445 ↗
  • Smith CC, Levis MJ, Perl AE, Hill JE, Rosales M, Bahceci E. Molecular profile of FLT3-mutated relapsed/refractory patients with AML in the phase 3 ADMIRAL study of gilteritinib. Blood Adv. 2022 Apr 12;6(7):2144-2155. doi: 10.1182/bloodadvances.2021006489. PubMed 35130342 ↗
  • Perl AE, Larson RA, Podoltsev NA, Strickland S, Wang ES, Atallah E, Schiller GJ, Martinelli G, Neubauer A, Sierra J, Montesinos P, Recher C, Yoon SS, Hosono N, Onozawa M, Chiba S, Kim HJ, Hasabou N, Lu Q, Tiu R, Levis MJ. Follow-up of patients with R/R FLT3-mutation-positive AML treated with gilteritinib in the phase 3 ADMIRAL trial. Blood. 2022 Jun 9;139(23):3366-3375. doi: 10.1182/blood.2021011583. PubMed 35081255 ↗
  • Perl AE, Martinelli G, Cortes JE, Neubauer A, Berman E, Paolini S, Montesinos P, Baer MR, Larson RA, Ustun C, Fabbiano F, Erba HP, Di Stasi A, Stuart R, Olin R, Kasner M, Ciceri F, Chou WC, Podoltsev N, Recher C, Yokoyama H, Hosono N, Yoon SS, Lee JH, Pardee T, Fathi AT, Liu C, Hasabou N, Liu X, Bahceci E, Levis MJ. Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML. N Engl J Med. 2019 Oct 31;381(18):1728-1740. doi: 10.1056/NEJMoa1902688. PubMed 31665578 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Access to anonymized individual participant level data collected during the study, in addition to study-related supporting documentation, is planned for studies conducted with approved product indications and formulations, as well as products terminated during development. Studies conducted with product indications or formulations that remain active in development are assessed after study completion to determine if Individual Participant Data can be shared. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Access to participant level data is offered to researchers after publication of the primary manuscript (if applicable) and is available as long as Astellas has legal authority to provide the data.

Access criteria: Researchers must submit a proposal to conduct a scientifically relevant analysis of the study data. The research proposal is reviewed by an Independent Research Panel. If the proposal is approved, access to the study data is provided in a secure data sharing environment after receipt of a signed Data Sharing Agreement.

Data sharing details ↗ · www.clinicaltrials.astellas.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2015 to primary completion in Sep 2018, 34 months.

Results were first posted in Oct 2019, 1 year 1 month after primary completion.

Of 43 industry-sponsored phase 3 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 62. This study's 34 months is below that.

Counting every sponsor, half of 121 studies reached it within 74 months; a quarter within 39 and three quarters within 99.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 16, 2015
First posted
Apr 21, 2015
StartActual
Oct 20, 2015
Primary completionActual
Sep 17, 2018
CompletionActual
Feb 25, 2025
Results first posted
Oct 17, 2019
Last update
Dec 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02421939
Responsible party
Sponsor
First posted
Apr 21, 2015
Start date
Oct 20, 2015
Primary completion
Sep 17, 2018
Completion
Feb 25, 2025
Results posted
Oct 17, 2019
Last update
Dec 4, 2025

Study contacts

Executive Medical Director
study director · Astellas Pharma Global Development, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Gilteritinib

Start the discussion